FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stephanos Hadziyannis

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Stephanos J Hadziyannis; V Sevastianos
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Stephanos J Hadziyannis; Irene Rapti; Vassilios Sevastianos; Dimitrios Vassilopoulos; Emilia S Hadziyannis
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Samuel S Lee; Diethelm Messinger; Stuart K Roberts; Fernando Tatsch; Edward J Gane; Stephanos J Hadziyannis; Kwang-Hyub Han; Hugh A Harley; Yves J Horsmans; Petr Husa; E Jenny Heathcote; Hanna Berak; Geoffrey M Dusheiko; Peter Ferenci
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stephanos Hadziyannis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stephanos J Hadziyannis; V Sevastianos
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Alimentary pharmacology & therapeutics 2013;37(4):491.
2012: Stephanos J Hadziyannis; Irene Rapti; Vassilios Sevastianos; Dimitrios Vassilopoulos; Emilia S Hadziyannis
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Gastroenterology 2012;143(3):629-36.e1.
2012: Samuel S Lee; Diethelm Messinger; Stuart K Roberts; Fernando Tatsch; Edward J Gane; Stephanos J Hadziyannis; Kwang-Hyub Han; Hugh A Harley; Yves J Horsmans; Petr Husa; E Jenny Heathcote; Hanna Berak; Geoffrey M Dusheiko; Peter Ferenci
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver 2012;32(8):1270-7.
2012: Stephanos J Hadziyannis
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Alimentary pharmacology & therapeutics 2012;35(12):1482.
2012: Stephanos J Hadziyannis
Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.
Alimentary pharmacology & therapeutics 2012;35(7):842-3; discussion 843-4.
2011: Stephanos J Hadziyannis
Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C.
Alimentary pharmacology & therapeutics 2011;34(1):102-3.
2011: Evangelos Cholongitas; George V Papatheodoridis; Emanuel K Manesis; Kaliopi Petraki; Dina Tiniakos; Stephanos J Hadziyannis
Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B.
Journal of medical virology 2011;83(7):1165-71.
2011: Stephanos J Hadziyannis
Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.
Journal of hepatology 2011;55(1):183-91.
2011: Michael W Fried; Stephanos J Hadziyannis; Diethelm Messinger; Mitchell L Shiffman; Stefan Zeuzem
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Journal of hepatology 2011;55(1):69-75.
2011: Irene N Rapti; Stephanos J Hadziyannis
Treatment of special populations with chronic hepatitis B infection.
Expert review of gastroenterology & hepatology 2011;5(3):323-39.
2011: Mahmoud A Khattab; Peter Ferenci; Stephanos J Hadziyannis; Massimo Colombo; Michael P Manns; Piero L Almasio; Rafael Esteban; Ayman A Abdo; Stephen A Harrison; Nazir Ibrahim; Patrice Cacoub; Mohammed Eslam; Samuel S Lee
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
Journal of hepatology 2011;54(6):1250-62.
2011: Stephanos J Hadziyannis
Milestones and perspectives in viral hepatitis B.
Liver international : official journal of the International Association for the Study of the Liver 2011;31 Suppl 1():129-34.
2010: Christoph Sarrazin; Mitchell L Shiffman; Stephanos J Hadziyannis; Amy Lin; Giuseppe Colucci; Hiroshi Ishida; Stefan Zeuzem
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Journal of hepatology 2010;52(6):832-8.
2010: Savino Bruno; Mitchell L Shiffman; Stuart K Roberts; Edward J Gane; Diethelm Messinger; Stephanos J Hadziyannis; Patrick Marcellin
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Hepatology (Baltimore, Md.) 2010;51(2):388-97.
2009: K Rajender Reddy; D Messinger; M Popescu; Stephanos J Hadziyannis
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.
Journal of viral hepatitis 2009;16(10):724-31.
2008: Dimitrios Vassilopoulos; I Rapti; Maria Nikolaou; Emilia S Hadziyannis; Stephanos J Hadziyannis
Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B.
Journal of viral hepatitis 2008;15(11):817-26.
2008: Nancy Reau; Stephanos J Hadziyannis; Diethelm Messinger; Michael W Fried; Donald M Jensen
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
The American journal of gastroenterology 2008;103(8):1981-8.
2008: K Rajender Reddy; S Govindarajan; P Marcellin; D Bernstein; J L Dienstag; Henry Jr. Bodenheimer; J Rakela; D Messinger; G Schmidt; A Ackrill; Stephanos J Hadziyannis
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Journal of viral hepatitis 2008;15(2):129-36.
2008: Melanie Deutsch; George V Papatheodoridis; Anastasia Tzakou; Stephanos J Hadziyannis
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis.
European journal of gastroenterology & hepatology 2008;20(1):5-9.
2008: Eric Snoeck; Stephanos J Hadziyannis; Claudio Puoti; Mark G Swain; Thomas Berg; Patrick Marcellin; Jean-Pierre Zarski; Karin Jorga; Stefan Zeuzem
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Liver international : official journal of the International Association for the Study of the Liver 2008;28(1):61-71.
2007: Evangelini Dimou; Vasilios Papadimitropoulos; Stephanos J Hadziyannis
The role of entecavir in the treatment of chronic hepatitis B.
Therapeutics and clinical risk management 2007;3(6):1077-86.
2007: Stephanos J Hadziyannis
Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".
Hepatology international 2007;1(2):281-4.
2007: Stephanos J Hadziyannis
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Expert opinion on investigational drugs 2007;16(6):777-86.
2007: Graham R Foster; Michael W Fried; Stephanos J Hadziyannis; Diethelm Messinger; Klaus Freivogel; Ola Weiland
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Scandinavian journal of gastroenterology 2007;42(2):247-55.
2007: Irene Rapti; Evangelini Dimou; Panayota Mitsoula; Stephanos J Hadziyannis
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Hepatology (Baltimore, Md.) 2007;45(2):307-13.
2007: Emanuel K Manesis; Emilia S Hadziyannis; Olga P Angelopoulou; Stephanos J Hadziyannis
Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.
Antiviral therapy 2007;12(1):73-82.
2006: Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary D Goodman; Jia Ma; Carol L Brosgart; Katyna Borroto-Esoda; Sarah Arterburn; Steven L Chuck
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Gastroenterology 2006;131(6):1743-51.
2006: Andreas Laras; John Koskinas; Evangelini Dimou; Ageliki Kostamena; Stephanos J Hadziyannis
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
Hepatology (Baltimore, Md.) 2006;44(3):694-702.
2006: Stephanos J Hadziyannis
New developments in the treatment of chronic hepatitis B.
Expert opinion on biological therapy 2006;6(9):913-21.
2006: Stephanos J Hadziyannis; George V Papatheodoridis
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.
Seminars in liver disease 2006;26(2):130-41.
2006: Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Hepatology (Baltimore, Md.) 2006;43(5):954-60.
2006: Robert P Perrillo; Robert G Gish; Marion Peters; Emmet B Keeffe; Alfredo Alberti; Maria Buti; W Graham E Cooksley; Michael W Fried; Stephanos J Hadziyannis; Yun-Fan Liaw; Nikolai Naoumov; Eugene R Schiff; Chloe L Thio; Naoky Tsai; Solko Schalm
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(2):233-48.
2006: Emanuel K Manesis; George V Papatheodoridis; Stephanos J Hadziyannis
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.
Alimentary pharmacology & therapeutics 2006;23(1):99-106.
2005: Ting-Tsung Chang; Robert G Gish; Stephanos J Hadziyannis; Janusz Cianciara; Mario Rizzetto; Eugene R Schiff; Giuseppe Pastore; Bruce R Bacon; Thierry Poynard; Shobha Joshi; Kenneth S Klesczewski; Alexandra Thiry; Ronald E Rose; Richard J Colonno; Robert G Hindes
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Gastroenterology 2005;129(4):1198-209.
2005: Savvas P Savvas; John Koskinas; C Sinani; AS Hadziyannis; F Spanou; Stephanos J Hadziyannis
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece.
Journal of viral hepatitis 2005;12(5):551-7.
2005: George V Papatheodoridis; Evangelini Dimou; Konstantinos Dimakopoulos; Spilios Manolakopoulos; Irene Rapti; George Kitis; Dimitrios Tzourmakliotis; Emanuel K Manesis; Stephanos J Hadziyannis
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Hepatology (Baltimore, Md.) 2005;42(1):121-9.
2005: Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary D Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
The New England journal of medicine 2005;352(26):2673-81.
2004: Stephanos J Hadziyannis; George V Papatheodoridis
Emerging treatments in chronic hepatitis B.
Expert opinion on emerging drugs 2004;9(2):207-21.
2004: Hassane Izzedine; Jean-Sébastien Hulot; Vincent Launay-Vacher; Patrick Marcellini; Stephanos J Hadziyannis; Graham Currie; Carol L Brosgart; Christopher E Westland; Sarah Arterbrun; Gilbert Deray
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.
Kidney international 2004;66(3):1153-8.
2004: Stephanos J Hadziyannis; George V Papatheodoridis
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Expert review of anti-infective therapy 2004;2(4):475-83.
2004: George V Papatheodoridis; Despina Papadelli; Evangelos Cholongitas; Dimitrios Vassilopoulos; Andreas Mentis; Stephanos J Hadziyannis
Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs.
The American journal of medicine 2004;116(9):601-5.
2004: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moisés Diago; Patrick Marcellin; Giuliano Ramadori; Henry Jr. Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Annals of internal medicine 2004;140(5):346-55.
2004: Michael W Fried; Stephanos J Hadziyannis
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Seminars in liver disease 2004;24 Suppl 2():47-54.
2004: George V Papatheodoridis; Stephanos J Hadziyannis
Review article: current management of chronic hepatitis B.
Alimentary pharmacology & therapeutics 2004;19(1):25-37.
2003: Stephanos J Hadziyannis; George V Papatheodoridis; Dimitrios Vassilopoulos
Precore mutant chronic hepatitis B - approach to management.
MedGenMed : Medscape general medicine 2003;5(4):1.
2003: Emanuel K Manesis; George V Papatheodoridis; Vasilios Sevastianos; Evangelos Cholongitas; Christos Papaioannou; Stephanos J Hadziyannis
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.
The American journal of gastroenterology 2003;98(10):2261-7.
2003: Stephanos J Hadziyannis
Treatment options for chronic hepatitis B not responding to interferon.
Journal of hepatology 2003;38(6):853-5.
2003: Stephanos J Hadziyannis; George V Papatheodoridis
Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.
Expert opinion on pharmacotherapy 2003;4(4):541-51.
2003: Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary D Goodman; Michael Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
The New England journal of medicine 2003;348(9):800-7.
2003: Stephanos J Hadziyannis; George V Papatheodoridis; Dimitrios Vassilopoulos
Treatment of HBeAg-negative chronic hepatitis B.
Seminars in liver disease 2003;23(1):81-8.
2003: Stephanos J Hadziyannis; George V Papatheodoridis
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).
Journal of hepatology 2003;39 Suppl 1():S172-6.
2002: George V Papatheodoridis; Emilia S Hadziyannis; Melanie Deutsch; Stephanos J Hadziyannis
Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
The American journal of gastroenterology 2002;97(8):2063-70.
2002: George V Papatheodoridis; Evangelini Dimou; Andreas Laras; Vassilios Papadimitropoulos; Stephanos J Hadziyannis
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
Hepatology (Baltimore, Md.) 2002;36(1):219-26.
2002: Spyros P Dourakis; Ioannis S Papanikolaou; Eftichios N Tzemanakis; Stephanos J Hadziyannis
Acute hepatitis associated with herb (Teucrium capitatum L.) administration.
European journal of gastroenterology & hepatology 2002;14(6):693-5.
2002: Emanuel K Manesis; George V Papatheodoridis; Stephanos J Hadziyannis
Serum HBV-DNA levels in inactive hepatitis B virus carriers.
Gastroenterology 2002;122(7):2092-3; author reply 2093.
2002: Andreas Laras; John Koskinas; Stephanos J Hadziyannis
In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter.
Virology 2002;295(1):86-96.
2002: Stephanos J Hadziyannis
Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy.
Journal of hepatology 2002;36(2):280-2.
2001: Stephanos J Hadziyannis; D Vassilopoulos
Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection.
Antiviral research 2001;52(2):91-8.
2001: Stephanos J Hadziyannis; D Vassilopoulos
Hepatitis B e antigen-negative chronic hepatitis B.
Hepatology (Baltimore, Md.) 2001;34(4 Pt 1):617-24.
2001: George V Papatheodoridis; Stephanos J Hadziyannis
Diagnosis and management of pre-core mutant chronic hepatitis B.
Journal of viral hepatitis 2001;8(5):311-21.
2001: Emanuel K Manesis; Stephanos J Hadziyannis
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.
Gastroenterology 2001;121(1):101-9.
2001: Ioannis S Papanikolaou; Spyros P Dourakis; V S Papadimitropoulos; Stephanos J Hadziyannis
Acute rhabdomyolysis following quail consumption.
Annals of Saudi medicine 2001;21(3-4):219-20.
2001: Spyros P Dourakis; A E Michael; Ioannis S Papanikolaou; E Nomikou; P Thalassinou; Stephanos J Hadziyannis
Autoimmune hepatitis associated with the antiphospholipid syndrome.
European journal of gastroenterology & hepatology 2001;13(5):591-3.
2001: George V Papatheodoridis; Vassilios Papadimitropoulos; Stephanos J Hadziyannis
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.
Alimentary pharmacology & therapeutics 2001;15(5):689-98.
2001: AS Hadziyannis; Christos Papaioannou; F Spanou; Emanuel K Manesis; Stephanos J Hadziyannis
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit.
Alimentary pharmacology & therapeutics 2001;15(4):551-7.
2001: George V Papatheodoridis; Emanuel K Manesis; Stephanos J Hadziyannis
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.
Journal of hepatology 2001;34(2):306-13.
2000: Stephanos J Hadziyannis; George V Papatheodoridis; Evangelini Dimou; Andreas Laras; Christos Papaioannou
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Hepatology (Baltimore, Md.) 2000;32(4 Pt 1):847-51.
2000: Spyros P Dourakis; Eftichios N Tzemanakis; C Sinani; Georgia Kafiri; Stephanos J Hadziyannis
Gliclazide-induced acute hepatitis.
European journal of gastroenterology & hepatology 2000;12(1):119-21.
1999: Spyros P Dourakis; Eftichios N Tzemanakis; Melanie Deutsch; Georgia Kafiri; Stephanos J Hadziyannis
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease.
European journal of gastroenterology & hepatology 1999;11(9):1055-8.
1999: Stephanos J Hadziyannis; George V Papatheodoridis
Long-term outcome of chronic hepatitis C treated with interferon.
Italian journal of gastroenterology and hepatology 1999;31(6):459-61.
1999: Stephanos J Hadziyannis; Emanuel K Manesis; A Papakonstantinou
Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study.
Journal of hepatology 1999;31(2):210-4.
1999: Andreas Laras; G Zacharakis; Stephanos J Hadziyannis
Absence of the negative strand of GBV-C/HGV RNA from the liver.
Journal of hepatology 1999;30(3):383-8.
1998: Stavroula Kostaridou; Vasilios Ladis; Antonis Kattamis; Andreas Laras; Stephanos J Hadziyannis
HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD.
Bone marrow transplantation 1998;22(9):919-21.
1998: Spyros P Dourakis; Alexandra Alexopoulou; Stephanos J Hadziyannis
Splenic infarct as a late complication of liver transplantation.
European journal of gastroenterology & hepatology 1998;10(9):805-8.
1998: Alexandra Alexopoulou; Ania M Owsianka; Georgia Kafiri; Spyros P Dourakis; W F Carman; Stephanos J Hadziyannis
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B.
Journal of hepatology 1998;29(3):345-51.
1998: Andreas Laras; John Koskinas; K Avgidis; Stephanos J Hadziyannis
Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.
Journal of viral hepatitis 1998;5(4):241-8.
1998: Stephanos J Hadziyannis
Fulminant hepatitis and the new G/GBV-C flavivirus.
Journal of viral hepatitis 1998;5(1):15-9.
1997: N Aiba; Michael J McGarvey; J Waters; Stephanos J Hadziyannis; Howard Thomas; Peter Karayiannis
The precore sequence of hepatitis B virus is required for nuclear localization of the core protein.
Hepatology (Baltimore, Md.) 1997;26(5):1311-7.
1997: Emanuel K Manesis; Christos Papaioannou; A Gioustozi; Georgia Kafiri; John Koskinas; Stephanos J Hadziyannis
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
Hepatology (Baltimore, Md.) 1997;26(3):734-9.
1997: Spyros P Dourakis; C Mayroyannis; Alexandra Alexopoulou; Stephanos J Hadziyannis
Prolonged cholestatic jaundice after endoscopic retrograde cholangiography.
Hepato-gastroenterology 1997;44(15):677-80.
1997: Stephanos J Hadziyannis
Review: hepatitis delta.
Journal of gastroenterology and hepatology 1997;12(4):289-98.
1997: Alexandra Alexopoulou; Peter Karayiannis; Stephanos J Hadziyannis; N Aiba; Howard Thomas
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species.
Journal of hepatology 1997;26(4):748-53.
1997: Spyros P Dourakis; C Sinani; Melanie Deutsch; E Dimitriadou; Stephanos J Hadziyannis
Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma.
European journal of gastroenterology & hepatology 1997;9(3):311-4.
1997: Nicolaos C Tassopoulos; M G Koutelou; H Polychronaki; M Paraloglou-Ioannides; Stephanos J Hadziyannis
Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial.
Journal of viral hepatitis 1997;4(6):387-94.
1997: Peter Karayiannis; Stephanos J Hadziyannis; J Kim; JM Pickering; M Piatak; G Hess; AJ Yun; Michael J McGarvey; J Wages; Howard Thomas
Hepatitis G virus infection: clinical characteristics and response to interferon.
Journal of viral hepatitis 1997;4(1):37-44.
1997: Stephanos J Hadziyannis
The spectrum of extrahepatic manifestations in hepatitis C virus infection.
Journal of viral hepatitis 1997;4(1):9-28.
1996: Spyros P Dourakis; Melanie Deutsch; Stephanos J Hadziyannis
Immune thrombocytopenia and alpha-interferon therapy.
Journal of hepatology 1996;25(6):972-5.
1996: Alexandra Alexopoulou; Peter Karayiannis; Stephanos J Hadziyannis; J Hou; JM Pickering; K Luo; Howard Thomas
Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity.
Journal of viral hepatitis 1996;3(4):173-81.
1995: Emanuel K Manesis; G Giannoulis; P Zoumboulis; I Vafiadou; Stephanos J Hadziyannis
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
Hepatology (Baltimore, Md.) 1995;21(6):1535-42.
1994: Spyros P Dourakis; Alexandra Alexopoulou; Stephanos J Hadziyannis
Fulminant hepatitis after flutamide treatment.
Journal of hepatology 1994;20(3):350-3.
1993: Stephanos J Hadziyannis; A S Hadziyannis; Spyros P Dourakis; Alexandra Alexopoulou; A Horsch; G Hess
Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection.
Hepato-gastroenterology 1993;40(6):588-92.
1993: Stephanos J Hadziyannis; Spyros P Dourakis; C Papaioannou; Alexandra Alexopoulou; E S Hadziyannis; A Gioustozi
Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece.
Progress in clinical and biological research 1993;382():259-66.
1993: A Yang; Peter Karayiannis; D Cheng; Stephanos J Hadziyannis; Howard Thomas; J Monjardino
Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection.
Progress in clinical and biological research 1993;382():145-8.
1993: Stephanos J Hadziyannis; G Giannoulis; E Hadziyannis; E Kaklamani; Alexandra Alexopoulou; Spyros P Dourakis; D Trichopoulos
Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma.
Journal of hepatology 1993;17 Suppl 3():S72-7.
1991: Stephanos J Hadziyannis; Urania Georgopoulou; E Psalidaki; A Budkowska
Pre-S1 and Pre-S2 gene-encoded proteins in liver and serum in chronic hepatitis delta infection.
Journal of medical virology 1991;34(1):14-9.
1991: Stephanos J Hadziyannis; C Papaioannou; Alexandra Alexopoulou
The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece.
Progress in clinical and biological research 1991;364():51-62.
1990: Anna Linda Zignego; F Dubois; Didier Samuel; Urania Georgopoulou; M Reynes; Paolo Gentilini; Alain Bismuth; Jean-Pierre Benhamou; Stephanos J Hadziyannis; Henri Bismuth
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients.
Journal of hepatology 1990;11(1):102-10.
1988: Stephanos J Hadziyannis
Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection.
Hepatology (Baltimore, Md.) 1988;8(3):696-8.
1987: Stephanos J Hadziyannis; A Hatzakis; C Papaioannou; C Anastassakos; E Vassiliadis
Endemic hepatitis delta virus infection in a Greek community.
Progress in clinical and biological research 1987;234():181-202.
1984: Anna S F Lok; Stephanos J Hadziyannis; I V Weller; M G Karvountzis; J Monjardino; P Karayiannis; L Montano; Howard Thomas
Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection.
Gut 1984;25(11):1283-7.